



## **Amit Agrawal**

### **Head, Portfolio Strategy & Management Global Drug Development**

Languages spoken: English, Hindi

Amit Agrawal is currently the Global Head of Portfolio Strategy and Management for Global Drug Development. He joined Novartis in Oct 2018 from Amgen where he was Head of Corporate Strategy. At Amgen, he was responsible for managing strategic planning process and communications to the Board, company-wide resource allocation planning and transformation, and driving M&A (e.g., Amgen's acquisition of Onyx) and capital investment projects. Prior to Amgen, he was at McKinsey and finished a post doc from MIT, where he developed and tested siRNA delivery formulations in ovarian cancer and Glioblastoma mouse models. He finished his graduate studies in Biomedical Engineering/nanotechnology from Georgia Tech where he developed reagents, assays, and instruments for ultrasensitive biological detection/ imaging at Georgia Tech. He has an undergraduate and master's degree in Chemistry from the Indian Institute of Technology, Kanpur. He has also worked at two startups, one of which was a small, public biotech company where he served as chief operating officer. He is an author on over 20 research articles and in his spare time he plays percussions for charitable causes.